For cases where desflurane or isoflurane were administered, there was a nonsignificant trend for a decrease in the intraoperative FGF (Table 3).
Hypothesis 2: Sevoflurane Consumption Was Reduced After the Absorbent Change
Sevoflurane consumption per minute of administration decreased by 0.039 mL/min (N = 8 of 8; 95% CI, 0.029 to 0.049 mL/min; P < 0.0001) after the change to the nonreactive absorbent (Table 3). Based on the hospital’s wholesale cost for sevoflurane, this would be equivalent to a reduction of $0.89 per hour (95% CI, −$0.67 to −$1.11). Hypothesis 2 was accepted.
There was a negative trend but not a significant decrease in the average number of bottles of sevoflurane purchased during each of the 10 4-week intervals before, compared with after, the change to the nonreactive absorbent decreased from 180.8 ± 6.3 to 160.7 ± 8.5 (N = 10 of 10, difference = −17.1; 95% CI, −17.4 to 16.8; P = 0.07). This was in the context of no significant change in inspired or expired agent concentrations, duration of cases, or number of cases (Table 3).
Hypothesis 3: Net Hospital Savings Would Be Positive After the Absorbent Change
To compare the hospital expenses before and after the absorbent switch, sevoflurane costs were determined by multiplying the number of bottles purchased by the average wholesale cost ($95 per bottle). Similarly, absorbent costs reflected the number of bags purchased times the unit cost. The difference in mean cost for the sum of the sevoflurane and absorbent purchases for each of the 10 4-week intervals before and after the absorbent switch was −$293 (N = 10 of 10, 95% CI, −$2853 to $2266; P = 0.81). Hypothesis 3 was rejected.
We conducted a sensitivity analysis to explore the financial implications at other hospitals given a range of sevoflurane acquisition costs, the differential costs between the current and a proposed replacement absorbent, and varying percentage reductions in sevoflurane consumption over a realistic range of parameters (Fig. 5, Supplemental Digital Content 4, http://links.lww.com/AA/B332). Hospital cost savings, at best, are likely to be modest, given the relatively low hourly cost of sevoflurane administration.
Hypothesis 4: Sevoflurane Wastage in Discarded 250-mL Bottles Would Be <1%
Fifty-two bottles were collected on 8 different days from the storage bucket in the anesthesia workroom, with samples ranging from 4 to 11 bottles; 1 bottle was missing its cap and was excluded from the analysis. The average amount of residual sevoflurane per bottle was 0.67 ± 0.06 mL (N = 8 collection days; 95% CI, 0.54 to 0.81 mL per bottle; P < 0.0001 vs 2.5 mL).
Monitoring Absorbent Exhaustion
Once the PICO2 reached 3 mm Hg for at least 3 consecutive minutes, the absorbent became exhausted within 95 minutes in most (i.e., >50%) canisters (Fig. 6). Because the mean duration of volatile anesthetic administration was 146 minutes during cases where sevoflurane was administered (Table 2), this indicated that the absorbent should be changed between cases if there was persistent rebreathing of CO2 ≥3 mm Hg. Otherwise, there would be a substantive chance that absorbent exhaustion would occur during the subsequent case, requiring an intraoperative absorbent change.
We were able to demonstrate a significant and sustained reduction in both FGF and calculated average sevoflurane consumption per minute. Providers changed their FGF behavior promptly upon the conversion from soda lime to the nonreactive absorbent. However, they did not achieve the desired sevoflurane FGF intraoperative target of 1.25 L/min, only reaching 1.51 L/min (P < 0.0001 compared with 1.25). Given the small additional benefit that would accrue from achieving the FGF goal, we elected not to implement additional measures, such as sending intraoperative pop-up messages to the workstations when the FGF was >1.0 L/min, as described by Nair et al.1 The measured reduction in sevoflurane ordering (9.5%) was less than the reduction in sevoflurane consumption (13.2%). However, when judged from the perspective of the hospital’s variable costs, the project appears to have been cost neutral, as savings from sevoflurane reduction were offset by the additional cost of the premium CO2 absorbent.
The reduction in FGF has a societal benefit from reducing the venting of anesthetic greenhouse gases into the environment. However, in perspective,28 the global contribution of volatile anesthetics released into the atmosphere only represents approximately 0.01% of CO2 released from the fossil fuel consumption.29,30 Furthermore, we were unable to find a life-cycle assessmentk of Litholyme or Sodasorb, so we cannot estimate accurately the differences in the environmental impact between the 2 absorbents. It is not sufficient simply to assess the decreased venting of the anesthetics when choosing an absorbent, as this ignores potential cradle to grave differences due to manufacturing, processing, packaging, transportation, recycling, and disposal.
Managing the process of pre-emptive absorbent replacement to avoid intraoperative changes was unexpectedly challenging. There were behavioral issues related to changing exhausted absorbent at the end of the day. Our providers and anesthesia technicians found that a color change of the indicator was not a reliable cue for when to change the absorbent.l Thus, monitoring PICO2 (a parameter measured by capnometers) during volatile general anesthetics, setting and activating the alarm limit, and responding appropriately when excessive rebreathing is noted are necessary. We initially applied empirical criteria for levels and duration of rebreathing to trigger an alert to our anesthesia technicians to change the absorbent between cases or before the first case of the day and then modified these based on our analysis of impending exhaustion. Although changing the absorbent is neither difficult nor time consuming, intraoperative replenishment creates a distraction from care of the patient. In addition, a circuit leak may occur if the canister does not seal properly, caustic dust may be released from the process of emptying and refilling the canister, and the level of volatile anesthetic may be inadvertently reduced, with the potential for patient movement or recall. Although we have an automated system to notify our technicians to change the absorbent, providers also need to take responsibility to monitor the PICO2 and ensure that nearly exhausted absorbent is replaced before starting the next case.
Our study has several limitations. First, our results cannot be directly applied to other hospitals, because volatile agent and absorbent acquisition costs, patterns of FGF, percentages of volatile agent wasted from discarding partially full bottles, willingness to reduce FGF during sevoflurane anesthesia, and levels of volatile anesthesia provided will vary. In addition, the ability to distribute personalized e-mail FGF reports to providers (as described in our recent review article5) or to implement a near real-time feedback system1 likely is necessary to achieve the reduction in sevoflurane consumption. However, the principles we describe with respect to assessing the cost utility of a program incorporating a change to a nonreactive absorbent and reduction of FGF during volatile agent administration are relevant. Appendix A can be used to conduct a sensitivity analysis on the financial impact of a potential change to a premium CO2 absorbent over a range of input parameters and anticipated changes. Regardless, facilities should not expect large savings, because sevoflurane is relatively inexpensive, nonreactive CO2 absorbents cost substantially more than conventional formulations, and the opportunity to greatly reduce FGF is likely limited. Prefilled disposable or recyclable canisters containing nonreactive absorbents are much more expensive than bulk product, as used in our study, and would have further reduced the net savings.
Another limitation is that the very small amount of wastage of sevoflurane in discarded bottles may have been subject to a Hawthorne effect. However, providers were told that we were collecting bottles to assess sevoflurane usage, not to assess how much they were wasting. In addition, over the 3-week collection period, there was no trend for increased residual volumes in the bottles, as might have been expected due to desensitization had this effect been present. Thus, our application of the method of batch means to measure wastage was appropriate.
Another limitation of our approach is that measurement of agent consumption by the anesthesia machine is vendor and model dependent and may also depend on the ability of one’s AIMS to record transmitted values. For example, Dräger Tiro® anesthesia machines are present in our ambulatory and out-of-OR locations and lack the ability to calculate agent consumption. Weighing vaporizers to determine agent consumption is a cumbersome process. At least during low FGF anesthesia, the Dion method21 of estimating volatile agent consumption is not sufficiently accurate to gauge savings.
A final limitation is that the hospital purchasing records may not have reflected accurately the consumption of either sevoflurane or CO2 absorbent within each 4-week batch. There was limited space for storage of these materials in the hospital’s stock room, so deliveries were made every 1 to 3 days, based on inventory. However, there were considerable supplies stored in the anesthesia drug carts and in the anesthesia work rooms, thereby buffering the impact of any ordering shortfalls.
In summary, we showed that a department can successfully transition to a premium nonreactive CO2 absorbent in a manner that is at least cost neutral by reducing the sevoflurane FGF to below limits recommended by the package insert. This was achieved in part by monitoring electronically for when to change the absorbent and automatically notifying the anesthesia technicians. However, the potential for other departments to achieve the limited success we realized depends on their ability to collect and analyze the necessary data, local policies regarding FGF and absorbent replacement, their ability to alter provider behavior through monitoring and feedback, and local prices.
APPENDIX A. SENSITIVITY ANALYSIS WORKSHEET FOR CHANGING TO A NONREACTIVE CARBON DIOXIDE ABSORBENT
The net cost of changing to a premium carbon dioxide (CO2) absorbent is the difference between the savings realized through reduced consumption of volatile agent via reduction of fresh gas flow (FGF) and the additional cost of the nonreactive absorbent compared with current absorbent expenses.
There will be uncertainty as to the extent that these potential savings can be realized due to several factors.
First, the new absorbent may have a different CO2-absorbing capacity than the current absorbent, which needs to be accounted for in the projected cost estimate. For example, if the new agent costs 2× as much but lasts 2× as long, then, ideally, the switch would be cost neutral. However, the full benefit of additional absorbent capacity may not be realized, so that needs to be accounted for in the sensitivity analysis.
Second, the total reduction in volatile agent consumption may not be proportional to the reduction in FGF during the intraoperative portion of cases (begin to end surgery). This is because during the induction of general anesthesia, higher gas flows and vaporizer concentrations will be utilized, and when FGF is reduced early into the anesthetic, higher vaporizer concentrations will be needed to maintain the same expired agent concentration compared with previously, when higher FGF was used. These factors are related to the uptake and distribution of volatile agent and will be more pronounced for relatively soluble agents (e.g., sevoflurane and isoflurane) than with more insoluble agents (desflurane). For short cases, the impact of FGF reduction during maintenance on agent consumption will be reduced, compared with longer cases, as the percentage of agent consumed during the early uptake phase will be larger than for long cases.
The following worksheet and the associated graph can be used to estimate the range of potential savings (or loses) that may be associated with the change to a premium CO2 absorbent. Worked examples are provided based for 3 hypothetical hospitals with varying costs for sevoflurane and absorbents, using a range of projected savings.
To perform a graphical sensitivity analysis, construct a rectangle on the contour plot in Figure 6 with the vertices at the minimum and maximum values for the annual estimated incremental absorbent costs (x-axis) and the projected annual sevoflurane savings (y-axis). Each colored band represents the net difference between the estimated sevoflurane savings and the additional cost of the premium absorbent. The area within the rectangle represents the range of potential net savings or losses. The 3 scenarios (A, B, and C) presented above are overlaid on this graph.
Name: Richard H. Epstein, MD, CPHIMS.
Contribution: This author helped design the study, conduct the study, analyze the data, and write the manuscript. He is the archival author.
Attestation: Richard H. Epstein attests to the integrity of the original data and the analysis reported in this manuscript and has approved the final manuscript.
Name: Franklin Dexter, MD, PhD.
Contribution: This author helped design the study, analyze the data, and write the manuscript.
Attestation: Franklin Dexter attests to the analysis reported in this manuscript and has approved the final manuscript.
Name: David P. Maguire, MD.
Contribution: This author helped prepare the manuscript.
Attestation: David P. Maguire attests to the integrity of the original data and approved the final manuscript.
Name: Niraj K. Agarwalla, DO.
Contribution: This author helped conduct the study and prepare the manuscript.
Attestation: Niraj K. Agarwalla attests to the integrity of the original data and approved the final manuscript.
Name: David M. Gratch, DO.
Contribution: This author helped prepare the manuscript.
Attestation: David M. Gratch attests to the integrity of the original data and approved the final manuscript.
Dr. Franklin Dexter is the Statistical Editor for Anesthesia & Analgesia. This manuscript was handled by Dr. Tong J. Gan, Section Editor for Ambulatory Anesthesiology and Perioperative Management, and Dr. Dexter was not involved in any way with the editorial process or decision.
a Patel N, Maguire D, Dexter F, Epstein RH. Reduction of fresh gas flow during administration of volatile anesthetic agents via monthly individualized e-mail feedback. 2014 Annual Meeting of the Society for Technology in Anesthesia. Available at: http://www.stahq.org/files/7013/9171/8017/13_Abstract_Epstein.pdf. Accessed January 3, 2015.
b Baxter. Sevoflurane, USP Package Insert. Available at: http://www.baxter.com/downloads/healthcare_professionals/products/SevofluranePI.pdf. Accessed January 3, 2015.
c Baxter Corporation. Sevoflurane Product Monograph. Available at: http://www.baxter.ca/en/downloads/product_information/SEVOFLURANE_PM_ENG_2013Nov26.pdf. Accessed January 2, 2015.
d Allied Healthcare Products. Material Safety Data Sheet: Litholyme. Available at: http://www.alliedhpi.com/images/Litholyme_MSDS.pdf. Accessed January 3, 2015.
e Allied Healthcare Products. Litholyme: a safer and more cost-effective carbon dioxide absorbent. Available at: http://www.litholyme.com/images/wp.pdf. Accessed January 3, 2015.
f Most of our absorbent canisters were cloudy from approximately 8 years of exposure to soda lime and were not able to be rendered transparent, despite vigorous cleaning. In addition, fresh nonreactive absorbent has a slightly purplish hue.
g Kuruma Y, Kita Y, Fujii S. Exchanging a CLIC absorber in the middle of surgery. APSF Newsletter, Winter 2013. Available at: http://www.apsf.org/newsletters/html/2013/winter/16ltr-CLICabsorber.htm. Accessed July 6, 2015.
h Gratch D, Maguire D, Epstein RH. Development of a system to pre-emptively identify impending carbon dioxide absorbent depletion during low fresh gas flow anesthesia to mitigate the need for intraoperative replacement during the case to follow. 2015 Annual Meeting of the International Anesthesia Research Society.
i Heesch R. Method for measuring the anesthetic agent consumption in a ventilation system. US Patent 20080029092 A1. Available at: http://www.google.com/patents/US20080029092. Accessed May 13, 2015.
j The method of batch means (bins) was used, as for analyzing most other operating room managerial data because mean fresh gas flows among successive cases represent a time series of correlated values.22–27 The data are correlated because (1) mean fresh gas flows vary among providers, (2) most providers perform multiple cases on days when delivering anesthesia, and (3) providers are often assigned over several-week intervals to work in the same areas with higher or lower prevalences of volatile anesthetic use. By aggregating cases over 4-week periods, the impact of such unmeasured relationships is mitigated.
k Wikpedia. Life-Cycle Assessment. Available at: http://en.wikipedia.org/wiki/Life-cycle_assessment. Accessed May 8, 2015.
l To put this in perspective, a competing nonreactive absorbent containing pure lithium hydroxide monohydrate in a solid-state matrix (SpiroLith®; Micorpore, Elkton, MD) lacks any color indicator.
1. Nair BG, Peterson GN, Neradilek MB, Newman SF, Huang EY, Schwid HA. Reducing wastage of inhalation anesthetics using real-time decision support to notify of excessive fresh gas flow. Anesthesiology. 2013;118:874–84
2. Sherman J, Le C, Lamers V, Eckelman M. Life cycle greenhouse gas emissions of anesthetic drugs. Anesth Analg. 2012;114:1086–90
3. McGain F, Story D, Kayak E, Kashima Y, McAlister S. Workplace sustainability: the “cradle to grave” view of what we do. Anesth Analg. 2012;114:1134–9
4. Dexter F, Maguire D, Epstein RH. Observational study of anaesthetists’ fresh gas flow rates during anaesthesia with desflurane, isoflurane and sevoflurane. Anaesth Intensive Care. 2011;39:460–4
5. Epstein RH, Dexter F, Patel N. Influencing anesthesia provider behavior using anesthesia information management system data for near real-time alerts and post hoc reports. Anesth Analg. 2015;121:678–92
6. Bito H, Ikeda K. Effect of total flow rate on the concentration of degradation products generated by reaction between sevoflurane and soda lime. Br J Anaesth. 1995;74:667–9
7. Neumann MA, Laster MJ, Weiskopf RB, Gong DH, Dudziak R, Förster H, Eger EI 2nd. The elimination of sodium and potassium hydroxides from desiccated soda lime diminishes degradation of desflurane to carbon monoxide and sevoflurane to compound A but does not compromise carbon dioxide absorption. Anesth Analg. 1999;89:768–73
8. Morio M, Fujii K, Satoh N, Imai M, Kawakami U, Mizuno T, Kawai Y, Ogasawara Y, Tamura T, Negishi A, Kumagai Y, Kawai T. Reaction of sevoflurane and its degradation products with soda lime: toxicity of the byproducts. Anesthesiology. 1992;77:1155–64
9. Keller KA, Callan C, Prokocimer P, Delgado-Herrera L, Friedman MB, Hoffman GM, Wooding WL, Cusick PK, Krasula RW. Inhalation toxicity study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats. Anesthesiology. 1995;83:1220–32
10. Frink EJ Jr, Malan TP, Morgan SE, Brown EA, Malcomson M, Gandolfi AJ, Brown BR Jr. Quantification of the degradation products of sevoflurane in two CO2
absorbents during low-flow anesthesia in surgical patients. Anesthesiology. 1992;77:1064–9
11. Bito H, Ikeda K. Closed-circuit anesthesia with sevoflurane in humans. Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit. Anesthesiology. 1994;80:71–6
12. Bito H, Ikeuchi Y, Ikeda K. Effects of low-flow sevoflurane anesthesia on renal function: comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia. Anesthesiology. 1997;86:1231–7
13. Kharasch ED, Frink EJ Jr, Zager R, Bowdle TA, Artru A, Nogami WM. Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. Anesthesiology. 1997;86:1238–53
14. Higuchi H, Sumita S, Wada H, Ura T, Ikemoto T, Nakai T, Kanno M, Satoh T. Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity. Anesthesiology. 1998;89:307–22
15. Obata R, Bito H, Ohmura M, Moriwaki G, Ikeuchi Y, Katoh T, Sato S. The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. Anesth Analg. 2000;91:1262–8
16. Ebert TJ, Arain SR. Renal responses to low-flow desflurane, sevoflurane, and propofol in patients. Anesthesiology. 2000;93:1401–6
17. Keijzer C, Perez RS, de Lange JJ. Compound A and carbon monoxide production from sevoflurane and seven different types of carbon dioxide absorbent in a patient model. Acta Anaesthesiol Scand. 2007;51:31–7
18. Struys MM, Bouche MP, Rolly G, Vandevivere YD, Dyzers D, Goeteyn W, Versichelen LF, Van Bocxlaer JF, Mortier EP. Production of compound A and carbon monoxide in circle systems: an in vitro comparison of two carbon dioxide absorbents. Anaesthesia. 2004;59:584–9
19. Baxter PJ, Garton K, Kharasch ED. Mechanistic aspects of carbon monoxide formation from volatile anesthetics. Anesthesiology. 1998;89:929–41
20. Luria I, Lampotang S, Schwab W, Cooper LA, Lizdas D, Gravenstein N. Automated, real-time fresh gas flow recommendations alter isoflurane consumption during the maintenance phase of anesthesia in a simulator-based study. Anesth Analg. 2013;117:1139–47
21. Dion P. The cost of anaesthetic vapours. Can J Anaesth. 1992;39:633
22. Ledolter J, Dexter F, Epstein RH. Analysis of variance of communication latencies in anesthesia: comparing means of multiple log-normal distributions. Anesth Analg. 2011;113:888–96
23. Dexter F, Epstein RH, Marcon E, Ledolter J. Estimating the incidence of prolonged turnover times and delays by time of day. Anesthesiology. 2005;102:1242–8
24. Dexter F, Epstein RH. Increased mean time from end of surgery to operating room exit in a historical cohort of cases with prolonged time to extubation. Anesth Analg. 2013;117:1453–9
25. Dexter F, Marcon E, Epstein RH, Ledolter J. Validation of statistical methods to compare cancellation rates on the day of surgery. Anesth Analg. 2005;101:465–73
26. Dexter F. High-quality operating room management research. J Clin Anesth. 2014;26:341–2
27. Austin TM, Lam HV, Shin NS, Daily BJ, Dunn PF, Sandberg WS. Elective change of surgeon during the OR day has an operationally negligible impact on turnover time. J Clin Anesth. 2014;26:343–9
28. Sulbaek Andersen MP, Nielsen OJ, Wallington TJ, Karpichev B, Sander SP. Medical intelligence article: assessing the impact on global climate from general anesthetic gases. Anesth Analg. 2012;114:1081–5
29. Sulbaek Andersen MP, Sander SP, Nielsen OJ, Wagner DS, Sanford TJ Jr, Wallington TJ. Inhalation anaesthetics and climate change. Br J Anaesth. 2010;105:760–6
© 2016 International Anesthesia Research Society
30. Friedlingstein P, Houghton RA, Marland G, Hackler J, Boden TA, Conway TJ, Canadell JG, Raupach MR, Ciais P, Le Quéré C. Update on CO2
emissions. Nat Geosci. 2010;3:811–2